BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia
Go back to BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia| (NASDAQ: BBIO) | Delayed: 82.93 +0.27 (0.33%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $82.66 | 52 Week High | $ | |||
| Open | $82.40 | 52 Week Low | $ | |||
| Day High | $83.53 | P/E | N/A | |||
| Day Low | $81.77 | EPS | $ | |||
| Volume | 1,530,869 | |||||
